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Background: Microsatellite instability (MSI) accounts for 15% of all colorectal tumours. Several specific clinicopathologicals (e.g., preference for
the proximal colon over the distal colon, improved prognosis and altered response to chemotherapeutics) are described for this subset of tumours.
This study aimed to analyse morphological, inflammatory and angiogenic features of MSI vs microsatellite stable (MSS) tumours.
Methods: Twenty-seven MSS and 29 MSI, TNM stage matched, colorectal tumours were selected from the archive of the Department of
Pathology, UZ Leuven. Morphology was analysed on haematoxylin–eosin sections. Immunohistochemistry for CD3, CD4, CD8, CD20 and CD68 was
used to map tumour infiltration in both a digital and traditional microscope-based manner for all distinct morphological components of the
tumour. CD31 immunostains were performed to assess angiogenesis.
Results: Morphological tumour heterogeneity was a marked feature of MSI tumours, occurring in 53% of the cases as compared with 11% of
the MSS tumours (Po0.001). Digital immune quantification showed an increased number of tumour-infiltrating cytotoxic T-lymphocytes
(CD8þ ) in MSI compared with MSS tumours for both the tumour (P¼ 0.02) and peritumoural area (P¼ 0.03). Traditional microscope-based
quantification confirmed these results (Po0.001 for both) and, in addition, revealed large numbers of CD68þ macrophages in the peritumoural
area of MSI cancers (P¼ 0.001). Moreover, traditional microscope-based analysis was able to distinguish between lymphocytes directly
infiltrating the tumoural glands (intra-epithelial) and those infiltrating only the neoplastic stroma around the glands (intratumoural).
Quantification showed high numbers of intra-epithelial CD3þ , CD4þ , CD8þ , CD20þ and CD68þ cells in MSI compared with MSS cancers
(Po0.001, P¼ 0.01, Po0.001, Po0.001 and P¼ 0.006, respectively). Higher microvessel density (MVD) was observed in MSI tumours compared
with their MSS counterpart.
Conclusions: Mixed morphology, reflecting tumour heterogeneity, is an important feature of MSI tumours and may have both diagnostic and
therapeutic impact. The inflammatory reaction also presented with significant differences in MSI vs MSS colorectal tumours. MSI cancers showed
mainly infiltration by cytotoxic T-cells in both the tumour and the close border around the tumour, as well as increased intra-epithelial infiltration in
contrast to MSS tumours. The type of immune cell and the compartment it resides in (intratumoural or intra-epithelial) depend both on MSI status
and morphology. Finally, MSI tumours showed a higher angiogenic capacity represented by an increased MVD, hinting for possible therapeutic
consequences.
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The molecular pathogenesis of colorectal cancer (CRC) is well
documented but not yet fully understood. About 94% of the cases
arises sporadically, a small minority of 5% has a hereditary origin
and 1% can be attributed to chronic inflammatory bowel disease
(Crohn’s disease, colitis ulcerosa) (Fearon, 2011). Two major
pathways are known in the development of colorectal carcinoma:
the chromosomal instability (CIN) pathway and the microsatellite
instability (MSI) pathway (Fleming et al, 2012; Bogaert and
Prenen, 2014). CIN is characterised by DNA aneuploidy and
mutations in different proto-oncogenes and tumour-suppressor
genes such as adenomatous polyposis coli tumour-suppressor gene,
Kirsten-ras (K-ras) proto-oncogene and p53 tumour-suppressor
gene and deleted in colon cancer tumour-suppressor gene. This
pathway accounts for the majority of sporadic CRCs and for CRCs
in the context of Familial Adenomatous Polyposis syndrome
(Fearon and Vogelstein, 1990; Salahshor et al, 1999). The MSI
pathway, defined as a status of genomic instability due to
a deficient DNA mismatch repair (MMR) system, accounts for
10–15% of sporadic CRCs. The MMR system consists of six
proteins (MLH1, MSH2, MSH3, MSH6, PMS1 and PMS2) that
interact to recognise and excise mismatches and mutations.
Thereby they allow re-synthesis and re-ligation of the strand by
DNA-polymerase d en DNA-ligase (Ionov et al, 1993; Thibodeau
et al, 1993; Alexander et al, 2001; Heinimann, 2013). In case of
MMR deficiencies, mostly due to hypermethylation of the MLH1
promotor region (Vilar and Gruber, 2010), the microsatellite
repeats located throughout the genome will shorten or lengthen
resulting in MSI (Kim et al, 2013). MSI is also associated with
CRCs arising in the context of hereditary nonpolyposis CRC, also
known as Lynch syndrome. This syndrome is characterised by
significantly increased risk of developing colorectal, endometrial
and several other cancers due to germ-line mutations in one of the
MMR genes (Ionov et al, 1993; Pino and Chung, 2010).
CRCs with MSI are associated with a specific histological,
mutational and clinical phenotype. Histologically, MSI tumours
often present as more poorly differentiated cancers, with
mucinous, signet cell and medullary differentiation frequently
observed. In addition, they are typically infiltrated by lymphocytes
and accompanied by an often prominent peritumoural Crohn’s-
like reaction (Shia et al, 2003). Because of the distinct pathogenesis
of MSI tumours, they often present with reduced frequencies of
APC, TP53 and KRAS mutations and with a higher incidence of
transforming growth factor, beta receptor II and BRAF mutations.
This altered mutational landscape results in a decreased signalling
through the WNT pathway (Cancer Genome Atlas Network, 2012;
Donehower et al, 2013). Clinically, this type of tumour is more
frequently located proximal to the splenic flexure, has a more
favourable prognosis and is less prone to lymph node and distant
metastatic spread (Reimers et al, 2013). Furthermore, studies have
demonstrated that there was no benefit of addition of 5-
fluorouracil (5-FU) chemotherapy for stages II and III MSI-H
CRCs; a trend towards worse clinical outcome for those receiving
5-FU was even detected (Ribic et al, 2003; Des Guetz et al, 2009).
However, other studies could not validate these findings (Sinicrope
et al, 2011). It has been suggested that the effects of anti-
VEGF would also vary according to MSI status (Hansen et al, 2011;
Kloor et al, 2014).
In this study, 57 CRCs were analysed with the aim to document
in depth the presence of intratumoural heterogeneity, inflamma-
tory reaction and angiogenic features in relation to MSI status.
MATERIALS AND METHODS
Patient selection. Twenty-nine specimen of CRC with known
MSI and 27 cases known to be microsatellite stable (MSS),
diagnosed between 2010 and 2013, were selected from the archive
of the pathology department of the University Hospitals of Leuven.
Patients who underwent preoperative radiotherapy or chemother-
apy were excluded from this study (to avoid interference with the
quality of immunohistochemistry). Furthermore, MSS cases
were matched to MSI tumours for TNM criteria (Seventh edition
AJCC/UICC). The diagnosis of CRC was established by histolo-
gical examination using the World Health Organisation (WHO)
criteria. Immunohistochemistry for MLH1, MSH2 and MSH6
was used to determine microsatellite stability status. Absence of
one of the MMR proteins in the tumour cells with positivity of the
internal control (lymphocytes) was used as criteria for MSI
diagnosis. Cases negative for one of the MMR genes by
immunohistochemistry were investigated for MSI by multiplex
PCR using a validated panel of 10 microsatellite markers (BAT
25, BAT 26, D5S346, D17S250, D2S123, TGFB-RII, BAT40,
D18S58, D17S787 and D18S69). Samples were graded as
MSI-high when instability was observed in 430% of the
Table 1. Clinicopathological characteristics
MSI MSS P-value
Mean age, years 67.2 70.6
Sex
Men 14/29 15/27 P¼0.6050
Women 15/29 12/27
Tumour site
Caecum 5/29 2/27 Po0.0001*
Ascending colon 15/29 7/27
Transverse colon 6/29 3/27
Descending colon 1/29 4/27
Sigmoid 2/29 6/27
Rectum 3/29 5/27
Proximal to splenic flexure 27/29 12/27
Differentiation grade
Wellþmoderately differentiated 8/29 21/27 P¼0.0002*
Poorly differentiated 21/29 6/27
Crohn’s-like reaction
Strongþmoderate 4/29 5/27 P¼0.7265
Poorþ absent 22/29 20/27
? 3/29 2/27
Fibrotic reaction
Strongþmoderate 9/29 13/27 P¼0.2640
Poorþ absent 17/29 12/27
? 3/29 2/27
T (tumour)
1 0/29 0/27 NA
2 1/29 1/27
3 15/29 17/27
4 13/29 9/27
N (lymph nodes)
0 16/29 14/27 NA
1 6/29 9/27
2 7/29 4/27
M (metastasis)
0 26/29 25/27 NA
1 3/29 2/27
Postoperative chemotherapy
Yes 13/29 19/27 NA
No 16/29 7/27
? 0/29 1/27
Recurrence
Yes 4/29 6/27 P¼0.4966
No 25/29 21/27
Abbreviations: MSI¼microsatellite instability; MSS¼microsatellite stable; NA¼not applicable.
*Po0.05.
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tested microsatellites that conform to the Bethesda guidelines
(Umar et al, 2004). Hypermethylation of the MLH1 promoter was
determined by MS-MLPA (SALSA MS-MLPA probe mix
ME011-B2, MRC-Holland, Amsterdam, the Netherlands). The
percentage of hypermethylation was the mean percentage
between the Deng C and Deng D region of the MLH1 promoter.
Percentages 415% were interpreted as positive for the hyper-
methylation of the MLH1 promoter. The presence of the BRAF
V600E mutation was demonstrated by Sanger sequencing.
Immunohistochemistry. Formalin-fixed, paraffin-embedded sections
were immunostained for CD3 (ready-to-use (RTU) rabbit polyclonal
anti-human antibodies; Dako, Glostrup, Denmark), CD4, CD8, CD20,
CD68, CD31 (RTU mouse monoclonal anti-human antibodies; Dako)
and peripheral node addressin (PNAd) clone MECA-79 (1/3000;
Biolegend, San Diego, CA, USA). All immunostains were performed on
5-mm-thick paraffin sections using the Dako autostainer. For
visualisation, the Envision Flex system (Dako) was used and antigen
retrieval was carried out using the Dako pretreatment module at
pH¼ 6. For PNAd, an additional incubation of 30min was necessary
with a rabbit anti-rat immunoglobuline (1/75 þ 10% normal human
serum, Dako).
Morphological features. Haematoxylin and eosin (H&E) sections
were investigated for different histological features, such as: degree
of differentiation, following the WHO criteria based on the
percentage of glands in the tumour (495% good, 50–95%
moderate and o50% poor), morphological pattern (glandular,
mucinous or solid), fibrotic, and Crohn’s-like reaction (absent,
poor, moderate or extensive). Tumours were scored as glandular
when gland formation was observed in the tumour without
excessive mucus production. The tumour was scored as mucinous
if 450% of the lesion was composed of pools of extracellular
mucin containing malignant epithelium. If o50% the lesion was
A
B C
ED
1 mm
100 µm
100 µm 100 µm
100 µm
Figure 1. Histologic and inflammatory reaction in MSI tumours. (A) H&E stain shows that this tumour is composed of a glandular and solid pattern.
(B, C) Histology of the glandular and solid pattern in more detail. (D, E) Immunohistochemistry for CD3 shows a combination of intratumoral and
intraepithelial lymphocytes in the glandular part of the MSI tumour, while mainly intra-epithelial lymphocytes were found in the solid part of the
MSI tumour.
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composed of mucin, the tumour was defined as a mucin-producing
tumour. Solid differentiation was assigned when sheets of
malignant cells in the absence of glandular formation were
observed. To score morphology, one section per centimetre
tumour was investigated with an average of 5 H&E slides with
tumour per case (ranging from 2 to 15). Furthermore, all resected
lymph nodes were checked for tumour metastasis with respect to
morphology according to the previous definitions according to
WHO criteria.
Immunoscores. Regarding immunohistochemistry, quantification
of immune cells was assessed in a digital and traditional
microscope-based manner. Only the representative FFPE block
per tumour was studied, with one section per stain. For the digital
quantification, slides were scanned utilising a digital slide scanner
(NanoZoomer 2.0-HT C9600, Hamamatsu Photonics K.K.,
Hamamatsu city, Japan). Later, the regions of interest of tumour
and peritumour, defined as 1-mm border around the tumour, were
encircled on the digital images followed by quantification of the
percentage of the positive tissue area (labelling index) in each
region with the Visiomorph software (Visiopharm, Hoersholm,
Denmark) (Verset et al, 2013). For the traditional microscope-
based analysis, positive cells were counted in 10 high-power fields
(HPF,  400) for the intra-epithelial (immune cells directly
infiltrating the neoplastic glands), intratumoural (immune cells
only infiltrating the neoplastic stroma surrounding the glands) and
peritumoural (1 HPF around the tumour) compartments.
The surface area of 1 HPF equals to 0.3025mm2. Analysis for
intra-epithelial and intratumoural compartment was carried out
for each morphological pattern individually. The Klintrup–
Makinen score for the tumour and the invasive margin was
determined using the representative H&E section of each case.
Therefore, immune infiltration by lymphocytes, neutrophilic and
eosinophilic granulocytes were scored. A score 0, 1, 2 or 3 was
assigned when respectively absent, weak (Patch-like infiltrate),
moderate (band-like infiltrate) or severe increase (very prominent
cup-shaped infiltrate) of each cell type was observed in the tumour
area or invasive margin. A score 2 or 3 for the invasive margin was
only assigned when destruction of cancer islets was observed.
Microvessel density (MVD). Angiogenesis in tumours was
evaluated by the CD31 staining: the number of blood vessels in
the tumour area was counted and divided by the tumour area with
MVD as a result (no. of vessels per mm2). Tumour area was
measured by a digital micro imaging device (Leica, DMD108, Leica,
Wetzlar, Germany).
Statistics. All statistical analyses were performed using the
GraphPad Prism 5 software (GraphPad Software, La Jolla, CA,
USA) and the Statistica Package (StatSoft, Tulsa, OK, USA).
Differences between MSS and unstable tumours were investigated
by comparing the cellular count values for each type of cells for
different regions in the tumour using the Mann–Whitney U-test.
The same statistical test was used to compare MVD between
both groups. To check the association of MSI status with
other categorical variables such as degree of differentiation,
tumour heterogeneity, fibrotic reaction and Crohn’s-like reaction,
contingency tables were designed and statistically compared with
Fisher’s exact test. Po0.05 was used as criterion for significance.
RESULTS
Clinicopathological characteristics. In total, 56 cases were
collected, 29 MSI and 27 MSS tumours matching for TNM stage.
The proportions of male and females were equally distributed in
each group and the mean age of the patients in the MSI group was
67.2 years, with the youngest patient being 27 years and the oldest
patient being 87 years. For the MSS group, the mean age was
slightly higher with a mean age of 70.6 years and a range from 50
to 83 years. In the group of MSI tumours, a high predominance for
the right colon was observed while MSS tumours were more
frequently observed in the left colon (P¼ 0.0004). As MSI and MSS
tumours were selected to match for TNM criteria, no statement
can be made with respect to this (Table 1). All MSI tumours were
scored as MSI high by means of PCR. Eight out of the 29 MSI
tumours occurred in the context of Lynch syndrome. Twenty-one
MSI tumours arose in sporadic context and presented frequently
with BRAFV600E mutations (66.6%) and variable levels of
hypermethylation of the MLH1 promoter (ranging from 21% to
89% and an average of 46.5%).
Morphological characteristics. In our series of TNM-matched
tumours, MSI cancers were significantly less differentiated
compared with MSS tumours (P¼ 0.0005). Seventeen MSI
tumours presented with a mucinous differentiation and 15 MSI
tumours with solid morphology. None of those patterns were
common in MSS tumours: the mucinous pattern was observed in
only three MSS cases, and solid differentiation was not identified in
the MSS group. A more pronounced Crohn’s-like reaction
(P¼ 0.72) or an altered degree of fibrosis (P¼ 0.26) in MSI
tumours compared with MSS cases was not noted.
Tumour heterogeneity in primary tumour and lymph node
metastasis. Sixteen of the MSI tumours (55%) were composed of
more than one morphological pattern, with combinations of
glandular, mucinous and/or solid differentiation areas (Figure 1).
This mixed morphology was observed in only 11% of the MSS
tumours (Po0.0001). Sporadic and Lynch-associated tumours
showed similar patterns of morphological heterogeneity, and BRAF
mutational status did not affect the occurrence of heterogeneity.
The glandular pattern was the most abundant pattern in the cohort
of MSI heterogeneous tumours (15 out of 16), followed by
mucinous and solid differentiation. Of the 16 MSI cases presenting
with morphological heterogeneity, 8 presented with positive lymph
nodes. In all but one case of the heterogeneous primary tumours
with a component of a glandular growth pattern, the glandular
component had metastasised to the lymph nodes. The solid pattern
had high metastatic capacity to the lymph nodes in contrast to the
mucinous differentiation pattern, which was only associated with
Table 2. Histological features
Case Primary tumour Lymph node metastasis
Pattern 1 Pattern 2 Pattern 3 Pattern 1 Pattern 2
1 Solid Mucinous Glandular Glandular Solid
2 Solid Glandular Glandular
3 Solid Glandular Solid
4 Mucinous Glandular Glandular Mucinous
5 Solid Mucinous Glandular
6 Glandular Solid Mucinous
7 Solid Mucinous Glandular Solid Glandular
8 Solid Mucinous Glandular Solid Glandular
9 Mucinous Glandular
10 Glandular Solid Mucinous
11 Solid Glandular Mucinous
12 Glandular Mucinous
13 Solid Mucinous Solid Mucinous
14 Mucinous Glandular
15 Solid Glandular Mucinous Glandular
16 Glandular Solid
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two lymph node metastasis in the MSI group. However, the group
of tumours with lymph node metastasis was too small for statistical
analysis (Table 2).
Inflammation. Digital immune cell quantification showed
increased numbers of tumour-infiltrating cytotoxic T-lymphocytes
(CD8þ ) in MSI compared with MSS tumours for both the tumour
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Figure 2. Analogous lymphocyte quantification of MSI and MSS tumours. (A–D) No differences in CD3þ or CD4þ lymphocyte infiltration for the
tumoral and peritumoral compartments were observed between MSI and MSS tumours. (E, F) Higher amount of infiltrating cytotoxic lymphocytes
(CD8þ ) were observed in the tumoral and peritumoral compartments of MSI compared with MSS cases. (G, H) Similar amounts of CD20þ
lymphocytes were quantified in the tumoral and peritumoral compartments of MSI and MSS tumours. (I, J) Macrophages (CD68þ ) are enriched in
the peritumoral area of MSI compared with MSS tumours; however, these differences were not seen in the tumoral area.
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(P¼ 0.02) and peritumoural (1mm border around the tumour)
regions (P¼ 0.03). Traditional microscope-based analysis con-
firmed those results (Po0.001 for both) (Figure 2). Moreover,
digital analysis showed a tendency of higher CD3þ T-cell
infiltration in MSI compared with MSS tumours (P¼ 0.06).
However, no other differences were found by means of digital
analysis for the other lymphocyte markers (Table 3). Immunohis-
tochemistry for CD68 displayed a lot of background signal and was
therefore not suitable for digital analysis. In contrast, traditional
quantification revealed large numbers of CD68þ macrophages in
the tumour (P¼ 0.05) and peritumoural area (P¼ 0.001) of MSS
tumours. Importantly, traditional microscope-based quantification
allowed to distinguish between lymphocytes directly infiltrating the
tumoural glands (intra-epithelial) and those infiltrating the
neoplastic stroma around the glands in the tumour region
(intratumoural). High numbers of intra-epithelial CD3þ ,
CD4þ , CD8þ , CD20þ and CD68þ cells were observed in
MSI compared with MSS tumours Po0.001, P¼ 0.01, Po0.001,
Po0.001 and P¼ 0.006, respectively). On the contrary, MSS
colorectal tumours were characterised by elevated levels of
intratumoural CD3þ , CD20þ and CD68þ cells (Po0.001,
P¼ 0.04 and P¼ 0.009, respectively; Figure 3, Table 4). Lympho-
cytes were quantified for all distinct morphologic compartments
within one tumour during traditional analysis. Glandular MSI
tumours presented with a combination of intratumoural and intra-
epithelial infiltrating CD3þ , CD4þ , CD8þ , CD20þ and
CD68þ cells while glandular MSS tumours showed mainly
intratumoural infiltration of CD3þ , CD20þ and CD68þ cells.
The mucinous compartment showed lower immune infiltration
compared with the other morphological components in both MSI
and MSS tumours. Solid differentiation was only observed in MSI
CRCs and characterised by a high abundance of intra-epithelial
CD3þ , CD4þ , CD8þ , CD20þ and CD68þ cells compared
with the glandular and mucinous differentiation. With respect to
the Klintrup–Makinen score, no differences were found in immune
infiltration for the tumour and invasive margin in MSI and MSS
tumours (Table 5).
Angiogenesis. Microsatellite unstable tumours presented with
higher densities of microvessels in comparison to MSS cancers
(P¼ 0.026). The median number of blood vessels in MSI cases
equals to 7.27 vessels per mm2 with a range from 3.1 to 20.0 vessels
per mm2, while MSS tumours presented with a median of 5.98
vessels per mm2 and a range from 2.8 to 16.1 microvessels per mm2
(Figure 4, Table 6). PNAd immunostains demonstrated that no
high endothelial venules were present in CRC, neither in MSI or in
MSS tumours.
DISCUSSION
In the present study, we demonstrated that there are major
differences between MSI and MSS colorectal tumours that present
on the morphological, inflammatory and the angionenic level.
Similar to other series, we found that MSI tumours tend to occur in
patients of a slightly younger age, with preponderance of the right
colon (Sinicrope et al, 2006; Jass, 2007). Previous studies
emphasised that MSI tumours show a reduced likelihood towards
metastasis in regional lymph nodes and distant organs, resulting in
an improved overall and disease-free survival (Gryfe et al, 2000). In
this study, we could not validate these findings as our samples were
chosen to match for TNM criteria.
Regarding morphology, tumour heterogeneity or polyclonality is
the most striking feature that distinguishes MSI from MSS CRCs in
our series. More than 50% of the MSI tumours presented with a
combination of two or more morphological patterns such as
glandular, mucinous and/or solid, while this was only the case in
11% of the MSS tumours. In addition, half of the heterogeneous
MSI tumours presented with affected lymph nodes, and it was
evident that the heterogeneity of the primary tumour was reflected
in the lymph node metastasis as heterogeneous lymph node
metastasis were observed in the majority (62%) of the hetero-
geneous primary tumours. The higher incidence of morphological
heterogeneity in MSI compared with MSS tumours may be
explained by the mutator phenotype of MSI tumours, resulting in
several molecular clones with possible distinct morphological
features, a hypothesis that remains to be verified. This observed
heterogeneity in MSI tumours may affect both diagnosis and
therapeutic approach in daily clinical practise. On the diagnostic
level, presence of morphological heterogeneity in a CRC biopsy
may be suggestive of MSI and should therefore warrant the
pathologist for further MSI testing. On the therapeutic level, it is
plausible and even highly likely that distinct morphological
components present with a distinct molecular background and
that those different morphological clones present with different
genetic footprints that form the base these days of individualised
therapy. Therefore new studies should investigate whether
Table 3. Labelling index of the different immune markers for each compartment and obtained by means of digital quantification
Mann-Whitney U-test (*significance at Po0.05)
Digital
analysis
Median
MSI
Lower quartile
MSI
Upper quartile
MSI
Median
MSS
Lower quartile
MSI
Upper quartile
MSS
2one-sided exact
P
CD3 tumour 0.043 0.014 0.090 0.020 0.016 0.037 0.06
CD3 peritumour 0.052 0.036 0.095 0.044 0.030 0.061 0.30
CD4 tumour 0.001 0.000 0.005 0.001 0.000 0.004 0.45
CD4 peritumour 0.006 0.002 0.018 0.004 0.001 0.008 0.29
CD8 tumour 0.016 0.007 0.051 0.005 0.005 0.013 0.02*
CD8 peritumour 0.021 0.014 0.032 0.014 0.007 0.023 0.03*
CD20 tumour 0.003 0.001 0.005 0.002 0.001 0.004 0.25
CD20
peritumour
0.019 0.008 0.030 0.013 0.006 0.031 0.73
CD68 tumour — — — — — —
CD68
peritumour
— — — — — —
Abbreviations: MSI¼microsatellite instability; MSS¼microsatellite stable.
*Po0.05.
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individual morphological components in one tumour present with
distinct mutational landscapes and distinct gene expression
profiles. Our observations confirm the new concept that it is
outdated to consider tumours as one homogeneous biological event
and that it is increasingly important for diagnostic, therapeutic and
prognostic approaches to recognise that tumours are composed of
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Figure 3. Analogous quantification of immune cells in the intra-epithelial (IE) and intratumoral (IT) compartments of MSI and MSS tumours. (A, C,
E, G, I) CD3þ , CD4þ , CD8þ , CD20þ and CD68þ cells are enriched in the IE component of MSI compared with MSS tumours. (B, H, J)
However, CD3þ , CD20þ and CD68þ cells are more prevalent in the IT compartment of MSS cases. (D, F) No differences in CD4þ and CD8þ
intratumoral lymphocyte infiltration were observed. The horizontal bars in the data distribution indicate medians.
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a combination of distinct tumour types. Therefore, all tumour
components should be investigated individually to overcome
inaccuracies due to the heterogeneous nature of the tumour
(Gerlinger et al, 2012; Bedard et al, 2013; Burrell et al, 2013).
Furthermore, on the morphologic level, we also found that MSI
tumours tend to be more poorly differentiated in comparison to
their TNM-matched, MSS counterparts in concordance with
known literature. The poorly differentiated display of MSI tumours
stems from the fact that MSI tumours often present with mucinous
or solid morphology while both morphological patterns are
uncommon features in MSS tumours. However, contrary to other
studies, no differences in fibrotic and Crohn’s-like reaction were
observed in our study, indicating that these features are not suitable
parameters for the recognition of MSI (Alexander et al, 2001;
Buckowitz et al, 2005).
Regarding the inflammatory tumour response, two quantifica-
tion methods were assessed to analyse and quantify the immune
infiltration: digital and traditional microscope-based analysis.
Results obtained from both methods were in high accordance as
they both showed significant higher levels of cytotoxic T-cells in
the tumour and peritumoural region of MSI compared with MSS
tumours. This inflammatory pattern may explain the better
prognosis for MSI tumours as cytotoxic T-cells supress micro-
metastasis. (Naito et al, 1998; Guidoboni et al, 2001; Prall et al,
2004; Laghi et al, 2009; Roxburgh et al, 2013; Ling et al, 2014).
Furthermore, traditional microscope-based analysis revealed
increased intra-epithelial infiltration in MSI tumours for all
Table 4. Results of analogous quantification of tumour-infiltrating lymphocytes counted in 10 HPF for the distinct compartments
Mann-Whitney U-test (*significance at Po0.05)
Analogous
analysis
Median
MSI
Lower quartile
MSI
Upper quartile
MSI
Median
MSS
Lower quartile
MSS
Upper quartile
MSS
2one-sided
exact P
CD3 tumour 350 197 715 341 145 440 0.4088
CD3 peritumour 1166 894 1758 1140 1108 1550 0.7605
CD3 intra-epithelial 384 157 1004 51 22 118 o0.0001*
CD3 intratumour 195 87 456 616 453 728 o0.0001*
CD4 tumour 27 8 62 29 8 68 1.000
CD4 peritumour 228 138 382 221 136 283 0.5517
CD4 intra-epithelial 19 4 35 2.5 0 12 0.0111*
CD4 intratumour 35 11 94 45 15 126 0.7098
CD8 tumour 227 115 566 98 52 140 0.0002*
CD8 peritumour 663 512 879 329 231 417 o0.0001*
CD8 intra-epithelial 267 121 651 59 21 88 o0.0001*
CD8 intratumour 126 93 243 130 85 180 0.5452
CD20 tumour 8 4 39 13 5 27 0.6308
CD20 peritumour 307 160 590 167 100 635 0.0738
CD20 intra-epithelial 4 0 45 0 0 1 0.0006*
CD20 intratumour 8 4 31 25 10 53 0.0424*
CD68 tumour 132 80 213 194 143 321 0.0503
CD68 peritumour 287 203 450 584 302 953 0.0010*
CD68 intra-epithelial 51 11 152 20 10 29 0.0057*
CD68 intratumour 159 120 302 356 251 611 0.0009*
Abbreviations: HPF¼ high-power fields; MSI¼microsatellite instability; MSS¼microsatellite stable.
*Po0.05.
Table 5. Klintrup–Makinen score for the tumour area and
invasion front with respect to MSI status
MSI—
tumour
MSI—invasive
margin
MSS—
tumour
MSS—invasive
margin
Score 0 2 5 0 0
Score 1 9 16 13 23
Score 2 9 6 12 3
Score 3 9 2 2 1
Abbreviations: MSI¼microsatellite instability; MSS¼microsatellite stable.
Table 6. Bloodvessel count, measurements of tumour area
and microvessel density
Average area
in mm2
(min–max)
Average blood
vessel count
(BVC) (min–max)
Average microvessel
density (in BVCmm2)
(min–max)
MSI 182.3 (79.7–421.0) 1502.3 (408–2812) 8.5 (3.1–20.0)
MSS 142.4 (55.6–304.8) 959.3 (294.0–2053) 7.1 (2.8–16.1)
Abbreviations: MSI¼microsatellite instability; MSS¼microsatellite stable.
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Figure 4. Higher microvessel density was observed in MSI compared
with MSS tumours. The horizontal bars in the data distribution indicate
medians.
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immune cell markers tested, indicating that an interaction between
specific MSI-related tumour features and T-cell receptor repertoire
allow for lymphocyte invasion into the neoplastic glands and not
just the neoplastic stroma. Some advantages of traditional
microscope-based quantification are the fact that it is able to
distinguish intratumoural- and intra-epithelial-infiltrating immune
cells, providing a bulk of extra information. Furthermore, the
human eye used in traditional quantification is able to distinct
background from authentic positivity, making it possible to
quantify tumour-infiltrating macrophages. Disadvantages of the
latter method are the fact that it is more prone to inter-observer
variability and more time consuming. On the contrary, the
advantages of digital quantification are the rather short time frame
and objectiveness of counting. Downsides of this technology are
difficulties in distinguishing positivity from background signal and
the fact that it is not yet possible to subdivide the tumour area into
an intra-epithelial and intratumoural compartment without
extensive manual interventions or the help of an additional and
specific epithelial marker.
In addition to the quantification, analysis of the immune
infiltrate shows that lymphocytic infiltration is heterogeneously
spread within one tumour. Both the density of lymphocytic
infiltration and the compartment the immune cells reside
in (intra-epithelial or intratumoural) depend on and highly
correlate with the morphological features of the tumour,
hence emphasising once more that tumours should be
studied and analysed on the clonal level (and that morphological
analysis can guide this process) (Figure 1). Mucinous MSI
and MSS tumours show barely no lymphocytic infiltration
compared with glandular and solid tumours. BRAF mutational
status nor Lynch syndrome affected the immune infiltration.
In the future, it would be of great interest to investigate
these difference in T-cell receptor repertoire for immune
cells residing in the intra-epithelial and intratumour
compartment individually with respect to morphology to unravel
why lymphocytes migrate into the neoplastic glands in
MSI tumours.
The Klintrup–Makinen score, which determines the amount of
lymphocytes, neutrophilic and eosinophilic granulocytes in the
tumour and invasive margin on an H&E section, could not validate
the observations from the digital and traditional microscope-based
immunoscores. This can be explained by the fact that the Klintrup–
Makinen score takes into account the amount of neutrophilic and
eosinophilic granulocytes, while this was not the case in our
scoring system.
Finally, besides morphological and inflammatory characteristics,
the angiogenic features were also compared for MSI and MSS
CRCs as angiogenesis can be a favourable or detrimental factor for
cancer progression. In our series, MSI tumours showed a
significant higher blood vessel density compared with MSS. In an
attempt to elucidate the function of the blood vessels in MSI
tumours, we performed immunohistochemistry for PNAd, a
marker for high endothelial venules (HEV). HEV are composed
of plumb cuboidal endothelial cells and are mainly located in
secondary lymphoid organs. Their main function is to enable
lymphocyte extravasation. Previous reports showed the presence of
HEV in solid tumours, including CRC (Martinet et al, 2011). These
findings were not validated in our cohort as no HEV were observed
in MSI nor MSS tumours. The difference in MVD between MSI
and MSS is striking, and it should be investigated whether this has
a therapeutic impact in patients treated with antiangiogenic
therapy.
In conclusion, we can state that morphological heterogeneity is
an important feature of MSI tumours that may reflect the
underlying molecular heterogeneity of the tumour, thereby
impacting both diagnostic and therapeutic procedures. Addition-
ally, the inflammatory reaction in MSI tumours is also
heterogeneous and clone dependent, with a massive amount of
(peri)tumour-infiltrating cytotoxic T-lymphocytes, while their
number is considerably lower in MSS tumours. Furthermore,
immune cells have a higher capacity to migrate into the intra-
epithelial compartment in MSI tumours that can depend on the
interaction of specific tumour characteristics with the T-cell
receptor repertoire. Finally, MSI tumours have a higher neo-
angiogenic capacity represented by the increased MVD in MSI
compared with MSS cancers but whether this may represent a
therapeutic target remains to be investigated.
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